Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.28994/fullpdf
Reference3 articles.
1. Why do phase III clinical trials in oncology fail so often?;Amiri-Kordestani;J Natl Cancer Inst.,2012
2. Clinical approval success rates for investigational cancer drugs;DiMasi;Clin Pharmacol Ther.,2013
3. Downfall of iniparib: a PARP inhibitor that doesn)t inhibit PARP after all;Sinha;J Natl Cancer Inst.,2014
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A high-throughput microfabricated platform for rapid quantification of metastatic potential;Science Advances;2024-08-16
2. Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system;Neoplasia;2023-12
3. Dose-finding based on feasibility and late-onset toxicity in adoptive cell therapy trials;Journal of Biopharmaceutical Statistics;2023-03-06
4. Recent advances in long-acting drug delivery systems for anticancer drug;Advanced Drug Delivery Reviews;2023-03
5. Isotonic design for phase I cancer clinical trials with late-onset toxicities;Journal of Biopharmaceutical Statistics;2023-01-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3